Literature DB >> 23807288

Generation of iPS cells from normal and malignant hematopoietic cells.

Keiki Kumano1, Shunya Arai, Mineo Kurokawa.   

Abstract

Induced pluripotent stem cells (iPSCs) can be generated from various types of cells with transduction of defined transcription factors. In addition to regenerative medicine, iPSCs have been used for the study of pathogenesis of inherited genetic diseases. Here, we presented the examples of the establishment of iPSCs from hematopoietic cells or fibroblasts from hematological disease patients. Hematopoietic cells would be a good donor source for establishing iPSCs owing to the high reprogramming efficiency. iPSCs can be generated not only from normal cells, but also from several types of tumor cells. However it is not so easy, because iPSCs from hematological malignancies have been established only from myeloproliferative neoplasms including chronic myelogenous leukemia (CML) and JAK2-V617F mutation-positive polycythemia vera (PV). iPSC technology has great potential to promote oncology research based on patient samples.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23807288     DOI: 10.1007/s12185-013-1385-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  44 in total

Review 1.  Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy.

Authors:  Hiroshi Watarai; Daisuke Yamada; Shin-ichiro Fujii; Masaru Taniguchi; Haruhiko Koseki
Journal:  Int J Hematol       Date:  2012-05-17       Impact factor: 2.490

2.  HLA-haplotype banking and iPS cells.

Authors:  Norio Nakatsuji; Fumiaki Nakajima; Katsushi Tokunaga
Journal:  Nat Biotechnol       Date:  2008-07       Impact factor: 54.908

3.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

Authors:  Jizhong Zou; Prashant Mali; Xiaosong Huang; Sarah N Dowey; Linzhao Cheng
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

4.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

5.  Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.

Authors:  Jacob Hanna; Marius Wernig; Styliani Markoulaki; Chiao-Wang Sun; Alexander Meissner; John P Cassady; Caroline Beard; Tobias Brambrink; Li-Chen Wu; Tim M Townes; Rudolf Jaenisch
Journal:  Science       Date:  2007-12-06       Impact factor: 47.728

6.  Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells.

Authors:  Angel Raya; Ignasi Rodríguez-Pizà; Guillermo Guenechea; Rita Vassena; Susana Navarro; María José Barrero; Antonella Consiglio; Maria Castellà; Paula Río; Eduard Sleep; Federico González; Gustavo Tiscornia; Elena Garreta; Trond Aasen; Anna Veiga; Inder M Verma; Jordi Surrallés; Juan Bueren; Juan Carlos Izpisúa Belmonte
Journal:  Nature       Date:  2009-05-31       Impact factor: 49.962

7.  Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases.

Authors:  Lin Ye; Judy C Chang; Chin Lin; Xiaofang Sun; Jingwei Yu; Yuet Wai Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-29       Impact factor: 11.205

8.  Regulation of somatic cell reprogramming through inducible mir-302 expression.

Authors:  Shi-Lung Lin; Donald C Chang; Chun-Hung Lin; Shao-Yao Ying; Davey Leu; David T S Wu
Journal:  Nucleic Acids Res       Date:  2010-09-24       Impact factor: 16.971

9.  Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach.

Authors:  Jordan R Plews; JianLiang Li; Mark Jones; Harry D Moore; Chris Mason; Peter W Andrews; Jie Na
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

10.  Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome.

Authors:  Xiaoning Mou; Yuanbo Wu; Henghua Cao; Qingzhang Meng; Qihui Wang; Chengchao Sun; Shengshou Hu; Yue Ma; Hao Zhang
Journal:  Stem Cell Res Ther       Date:  2012-04-18       Impact factor: 6.832

View more
  5 in total

1.  Reprogramming bladder cancer cells for studying cancer initiation and progression.

Authors:  Banu Iskender; Kenan Izgi; Halit Canatan
Journal:  Tumour Biol       Date:  2016-07-25

2.  Hematopoietic defects and iPSC disease modeling: lessons learned.

Authors:  James M Kelley; George Q Daley
Journal:  Immunol Lett       Date:  2013-09-25       Impact factor: 3.685

Review 3.  The Stem Cell Revolution Revealing Protozoan Parasites' Secrets and Paving the Way towards Vaccine Development.

Authors:  Alena Pance
Journal:  Vaccines (Basel)       Date:  2021-01-31

4.  Reprogramming cancer cells to pluripotency: an experimental tool for exploring cancer epigenetics.

Authors:  Stefan Stricker; Steven Pollard
Journal:  Epigenetics       Date:  2014-03-31       Impact factor: 4.528

5.  Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state.

Authors:  Elena V Skvortsova; Sergey A Sinenko; Alexey N Tomilin
Journal:  Oncotarget       Date:  2018-10-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.